CBUS Stock Overview
An agricultural biotechnology company, develops and licenses gene edited plant traits using gene editing technologies to enhance farming productivity or produce renewable low carbon plant products. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Cibus, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.43 |
| 52 Week High | US$19.56 |
| 52 Week Low | US$1.40 |
| Beta | 1.71 |
| 1 Month Change | 34.25% |
| 3 Month Change | -3.57% |
| 1 Year Change | -87.04% |
| 3 Year Change | -84.83% |
| 5 Year Change | -98.88% |
| Change since IPO | -99.57% |
Recent News & Updates
Recent updates
Licensing And EU Harmonization Will Open New Markets
Apr 09 Transitioning to a commercial trait company and leveraging licensing agreements can unlock new revenue streams and enhance market penetration.Cibus: Expanding Opportunities And Growing Accessible Market
Jan 12Is Cibus, Inc. (NASDAQ:CBUS) Trading At A 44% Discount?
Oct 19
Does Cibus (NASDAQ:CBUS) Have A Healthy Balance Sheet?
Sep 07Shareholder Returns
| CBUS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 15.7% | -2.6% | 3.9% |
| 1Y | -87.0% | -12.1% | 11.6% |
Return vs Industry: CBUS underperformed the US Biotechs industry which returned -15.3% over the past year.
Return vs Market: CBUS underperformed the US Market which returned 8% over the past year.
Price Volatility
| CBUS volatility | |
|---|---|
| CBUS Average Weekly Movement | 15.2% |
| Biotechs Industry Average Movement | 11.9% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 4.2% |
Stable Share Price: CBUS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CBUS's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 158 | Peter Beetham | www.cibus.com |
Cibus, Inc., an agricultural biotechnology company, develops and licenses gene edited plant traits using gene editing technologies to enhance farming productivity or produce renewable low carbon plant products. It focuses on trait productivity in the productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients, which enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases. The company was formerly known as Calyxt, Inc. and changed its name to Cibus, Inc. in June 2023.
Cibus, Inc. Fundamentals Summary
| CBUS fundamental statistics | |
|---|---|
| Market cap | US$73.75m |
| Earnings (TTM) | -US$274.84m |
| Revenue (TTM) | US$4.75m |
16.7x
P/S Ratio-0.3x
P/E RatioIs CBUS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CBUS income statement (TTM) | |
|---|---|
| Revenue | US$4.75m |
| Cost of Revenue | US$0 |
| Gross Profit | US$4.75m |
| Other Expenses | US$279.59m |
| Earnings | -US$274.84m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -8.41 |
| Gross Margin | 100.00% |
| Net Profit Margin | -5,784.87% |
| Debt/Equity Ratio | 0.7% |
How did CBUS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/12 22:21 |
| End of Day Share Price | 2025/05/12 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cibus, Inc. is covered by 12 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matthew Venezia | Alliance Global Partners |
| Donald McLee | Berenberg |
| Kenneth Zaslow | BMO Capital Markets Equity Research |